E&C delays vote on drug pricing bill image

Politico, February 6, 2017
Sarah Karlin-Smith, quoting Rachel E. Sachs (Academic Fellow Alumna)


Read the full article

From the article:

On cost: studies have found that it usually takes a handful of generic drugscompeting for market share for prices to drop. “You usually need to get to something like three or four generics to really make a difference,” said Rachel Sachs of Washington University in St. Louis. Not to mention that most people believe concerns over high-priced drugs extend beyond the companies targeted by this bill. “This is just one small, small piece of the overall debate we are having around drug prices. There are many different reasons why drugs are priced high. This may help somewhat in dealing with the Martin Shkreli’s of the world, but does nothing for the new expensive cancer medicines or new medicines for other sorts of chronic conditions,” Sachs said. Now we wait and see if the committee crafts stronger legislation…

Read more here!

bioethics fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation